Hematologic toxicity in anal cancer patients during combined chemo-radiation: a radiation oncologist perspective

References

• Franco P, Mistrangelo M, Arcadipane F, et al. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series. Cancer Invest. 2015;33:259–266.
   PubMed Web of Science ®Google Scholar
• Nigro ND, Vaitkevicius VK, Considine B Jr. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum. 1974;17:354–356.
   PubMed Web of Science ®Google Scholar
• Franco P, Arcadipane F, Ragona R, et al. Early-stage node negative (T1-T2N0) anal cancer treated with simultaneous integrated boost radiotherapy and concurrent chemotherapy. Anticancer Res. 2016;36:1943–1948.
   PubMed Web of Science ®Google Scholar
• Franco P, Arcadipane F, Ragona R, et al. Locally advanced (T3-T4 or N+) anal cancer treated with simultaneous integrated boost radiotherapy and concurrent chemotherapy. Anticancer Res. 2016;36:2027–2032.
   PubMed Web of Science ®Google Scholar
• Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. Jama. 2008;299:1914–1921.
   PubMed Web of Science ®Google Scholar
• Julie DA, Oh JH, Apte AP, et al. Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma. Acta Oncol. 2016;55:208–216.
   PubMed Web of Science ®Google Scholar
• Mauch P, Constine L, Greenberger J, et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys. 1995;31:1319–1339.
   PubMed Web of Science ®Google Scholar
• Filippi AR, Franco P, Ricardi U. Is clinical radiosensitivity a complex genetically controlled event? Tumori. 2006;92:87–91.
   PubMed Web of Science ®Google Scholar
• Lujan AE, Mundt AJ, Yamada SD, et al. Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57:516–521.
   PubMed Web of Science ®Google Scholar
• Mell LK, Schomas DA, Salama JK, et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:1431–1437.
   PubMed Web of Science ®Google Scholar
• Ellis RE. The distribution of active bone marrow in the adult. Phys Med Biol. 1961;5:255–258.
   PubMed Web of Science ®Google Scholar
• Jianyang W, Yuan T, Yuan T, et al. A prospective phase II study of magnetic resonance imaging guided hematopoietical bone marrow-sparing intensity-modulated radiotherapy with concurrent chemotherapy for rectal cancer. Radiol Med. 2016;121:308–314.
   PubMed Web of Science ®Google Scholar
• Mell LK, Tiryaki H, Ahn KH, et al. Dosimetric comparison of bone marrow-sparing intensity modulated radiotherapy versus conventional techniques for treatment of cervical cancer. Int J Radiat Oncol Biol Phys. 2008;71:1504–1510.
   PubMed Web of Science ®Google Scholar
• Cristy M. Active bone marrow distribution as a function of age in humans. Phys Med Biol. 1981;26:389–400.
   PubMed Web of Science ®Google Scholar
• Blebea JS, Houseni M, Torigian DA, et al. Structural and functional imaging of normal bone marrow and evaluation of its age-related changes. Semin Nucl Med. 2007;37:1129–1133.
   Web of Science ®Google Scholar
• Vogler JB 3rd, WA Murphy. Bone marrow imaging. Radiology. 1988;168:679–693.
   PubMed Web of Science ®Google Scholar
• Filippi AR, Franco P, Galliano M, et al. Peripheral blood complete remission after splenic irradiation in mantle-cell lymphoma with 11q22-23 deletion and ATM inactivation. Radiat Oncol. 2006;1:35.
   PubMed Web of Science ®Google Scholar
• Sykes M, Chu F, Savel H, et al. The effects of varying dosages of irradiation upon sternal marrow regeneration. Radiology. 1964;83:1563–1570.
   Web of Science ®Google Scholar
• Tubiana M, Frindel E, Croizat H. Effects of radiation on bone marrow. Pathol Biol (Paris). 1979;27:326–334.
   PubMed Web of Science ®Google Scholar
• Rubin P, Scarantino C. The bone marrow organ: the critical structure in radiation-drug interaction. Int J Radiat Oncol Biol Phys. 1978;4:3–23.
   PubMed Web of Science ®Google Scholar
• Franco P, Arcadipane F, Ragona R, et al. Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients. Br J Radiol. 2016;89(1060):20150832.
   PubMed Web of Science ®Google Scholar
• Roeske JC, Lujan A, Reba RC, et al. Incorporation of SPECT bone marrow imaging into intensity modulated whole-pelvic radiation therapy treatment planning for gynecologic malignancies. Radiother Oncol. 2005;77:11–17.
   PubMed Web of Science ®Google Scholar
• Agool A, Schot BW, Jager PL, et al. 18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment. J Nucl Med. 2006;47:1592–1598.
   PubMed Web of Science ®Google Scholar
• Hayman JA, Callahan JW, Herscjtal A, et al. Distribution of proliferating bone marrow adult cancer patients determined using FLT-PET imaging. Int J Radiat Oncol Biol Phys. 2011;79:847–852.
   PubMed Web of Science ®Google Scholar
• McGuire SM, Menda Y, Boles Ponto LL, et al. 3ʹ-deoxy-3ʹ-[18F]fluorothymidine PET quantification of bone marrow response to radiation dose. Int J Radiat Oncol Biol Phys. 2011;81:888–893.
   PubMed Web of Science ®Google Scholar
• Campbell BA, Callahan J, Bressel M, et al. Distribution atlas of proliferating bone marrow in non-small cell lung cancer patients measured by FLT-PET/CT imaging, with potential applicability in radiation therapy planning. Int J Radiat Oncol Biol Phys. 2015;92:1035–1043.
   PubMed Web of Science ®Google Scholar
• McGuire SM, Menda Y, Boles Ponto LL, et al. Spatial mapping of functional pelvic bone marrow using FLT PET. J Appl Clin Med Phys. 2014;15:4780.
   PubMed Web of Science ®Google Scholar
• Franco P, Arcadipane F, Ragona R, et al. Dose to specific subregions of pelvic bone marrow defined with FDG-PET as a predictor of hematologic nadirs during concomitant chemoradiation in anal cancer patients. Med Oncol. 2016;33:72.
   PubMed Web of Science ®Google Scholar
• UKCCCR Anal cancer Trial Working Party. UK Co-ordination Committee on Cancer Research: epidermoid anal cancer: results from the UKCCCR randomized trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet. 1996;348:1049–1054.
   PubMed Web of Science ®Google Scholar
• Bartelink H, Roelofsen F, Eschwege P, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040–2049.
   PubMed Web of Science ®Google Scholar
• Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527–2539.
   PubMed Web of Science ®Google Scholar
• James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. 2013;14:516–524.
   PubMed Web of Science ®Google Scholar
• Peiffert D, Tournier-Rangeard L, Gérard JP, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012;30:1941–1948.
   PubMed Web of Science ®Google Scholar
• Merlotti A, Alterio D, Vigna-Taglianti R, et al. Italian Association of Radiation Oncology. Technical guidelines for head and neck cancer IMRT on behalf of the Italian Association of Radiation Oncology - Head and Neck Working Group. Radiat Oncol. 2014;9:264.
   PubMed Web of Science ®Google Scholar
• Franco P, Zeverino M, Migliaccio F, et al. Intensity-modulated adjuvant whole breast radiation delivered with static angle tomotherapy (TomoDirect): a prospective case series. J Cancer Res Clin Oncol. 2013;139:1927–1936.
   PubMed Web of Science ®Google Scholar
• Franco P, Zeverino M, Migliaccio F, et al. Intensity-modulated and hypofractionated simultaneous integrated boost adjuvant breast radiation employing statics ports of tomotherapy (TomoDirect): a prospective phase II trial. J Cancer Res Clin Oncol. 2014;140:167–177.
   PubMed Web of Science ®Google Scholar
• Milano MT, Jani AB, Farrey KJ, et al. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2005;63:354–361.
   PubMed Web of Science ®Google Scholar
• Salama JK, Mell LK, Schomas DA, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal cancer patients: a multicenter experience. J Clin Oncol. 2007;25:4581–4586.
   PubMed Web of Science ®Google Scholar
• Pepek JM, Willett CG, Wu QJ, et al. Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. Int J Radiat Oncol Biol Phys. 2010;78:1413–1419.
   PubMed Web of Science ®Google Scholar
• Bazan JG, Hara W, Hsu A, et al. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer. 2011;117:3342–3351.
   PubMed Web of Science ®Google Scholar
• Vieillot S, Fenoglietto P, Lemanski C, et al. IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer Center. Radiat Oncol. 2012;7:45.
   PubMed Web of Science ®Google Scholar
• DeFoe SG, Beriwal S, Jones H, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma–clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network. Clin Oncol. 2012;24:424–431.
   PubMed Web of Science ®Google Scholar
• Kachnic LA, Tsai HK, Coen JJ, et al. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys. 2012;82:153–158.
   PubMed Web of Science ®Google Scholar
• Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86:27–33.
   PubMed Web of Science ®Google Scholar
• Chuong MD, Freilich JM, Hoffe SE, et al. Intensity-modulated radiation therapy vs. 3D conformal radiation therapy for squamous cell carcinoma of the anal canal. Gastrointest Cancer Res. 2013;6:39–45.
   PubMedGoogle Scholar
• Belgioia L, Vagge S, Agnese D, et al. Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity. World J Gastroenterol. 2015;21:10688–10696.
   PubMed Web of Science ®Google Scholar
• Call JA, Prendergast BM, Jensen LG, et al. Intensity-modulated radiation therapy for anal cancer: results from a multi-institutional retrospective cohort study. Am J Clin Oncol. 2016;39:8–12.
   PubMed Web of Science ®Google Scholar
• Mell LK, Kochanski JD, Roeske JC, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:1356–1365.
   PubMed Web of Science ®Google Scholar
• Robinson M, Sabbagh A, Muirhead R, et al. Modeling early haematologic adverse events in conformal and intensity-modulated pelvic radiotherapy in anal cancer. Radiother Oncol. 2015;117:246–251.
   PubMed Web of Science ®Google Scholar
• Klopp AH, Moughan J, Portelance L, et al. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer. Int J Radiat Oncol Biol Phys. 2013;86:83–90.
   PubMed Web of Science ®Google Scholar
• Cheng JC, Bazan JG, Wu JK, et al. Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal. Pract Radiat Oncol. 2014;4:198–206.
   PubMedGoogle Scholar
• Rose BS, Liang Y, Lau SK, et al. Correlation between radiation dose to 18FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012;82:1185–1191.
   PubMed Web of Science ®Google Scholar
• Rose BS, Jee KW, Niemierko A, et al. Irradiation of FDG-PET-defined active bone marrow subregions and acute hematologic toxicity in anal cancer patients undergoing chemoradiation. Int J Radiat Oncol Biol Phys. 2016;94:747–754.
   PubMed Web of Science ®Google Scholar
• Bazan JG, Luxton G, Mok EC, et al. Normal tissue complication probability modeling of acute hematological toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2012;84:700–706.
   PubMed Web of Science ®Google Scholar
• Franco P, Ragona R, Arcadipane F, et al. Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer. Clin Transl Oncol. 2017;19:67–75.
   PubMed Web of Science ®Google Scholar
• Rose BS, Aydogan B, Liang Y, et al. Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011;79:800–807.
   PubMed Web of Science ®Google Scholar
• Albuquerque K, Giangreco D, Morrison C, et al. Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow-sparing pelvic IMRT. Int J Radiat Oncol Biol Phys. 2011;79:1043–1047.
   PubMed Web of Science ®Google Scholar
• Yang TJ, Oh JH, Apte A, et al. Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy. Radiother Oncol. 2014;113:29–34.
   PubMed Web of Science ®Google Scholar
• Wan J, Liu K, Li K, et al. Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy? Radiat Oncol. 2015;10:162.
   PubMed Web of Science ®Google Scholar
• Wang J, Tian Y, Tang Y, et al. A prospective phase II study og magnetic resonance imaging guided hematopoietical bone marrow-sparing intensity-modulated radiotherapy with concurrent chemotherapy for rectal cancer. Radiol Med. 2016;121:308–314.
   PubMed Web of Science ®Google Scholar
• Wang J, Tian Y, Tang Y, et al. A Phase II prospective nonrandomized trial of magnetic resonance imaging-guided hematopoietic bone marrow-sparing radiotherapy for gastric cancer patients with concurrent chemotherapy. Onco Targets Ther. 2016;9:2701–2707.
   PubMed Web of Science ®Google Scholar
• Sini C, Fiorino C, Perna L, et al. Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation. Radiother Oncol. 2016;118:79–84.
   PubMed Web of Science ®Google Scholar
• Deek MP, Benenati B, Kim S, et al. Thoracic vertebral body irradiation contributes to acute hematologic toxicity during chemoradiation therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2016;94:147–154.
   PubMed Web of Science ®Google Scholar
• Zhu H, Zakeri K, Vaida F, et al. Longitudinal study of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. J Med Imaging Radiat Oncol. 2015;59:386–393.
   PubMed Web of Science ®Google Scholar
• Bazan JG, Luxton G, Kozak MM, et al. Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2013;87:983–991.
   PubMed Web of Science ®Google Scholar
• Franco P, Ragona R, Arcadipane F, et al. Lumbar-sacral bone marrow dose modeling for acute hematological toxicity in anal cancer patients treated with concurrent chemo-radiation. Med Oncol. 2016;33:137.
   PubMed Web of Science ®Google Scholar
• Elicin O, Callaway S, Prior JO, et al. [18F] FDG-PET standard uptake value as a metabolic predictor of bone marrow response to radiation: impact on acute and late hematologic toxicity in cervical cancer patients treated with chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2014;90:1099–1107.
   PubMed Web of Science ®Google Scholar
• Sonal S, Noticewala BA, Li N, et al. Longitudinal changes in active bone marrow for cervical cancer patients treated with concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. Forthcoming. DOI:10.1016/j.ijrobp.2016.11.033
   Google Scholar
• Mell LK, Sirak I, Wei L, et al. Bone marrow-sparing intensity modulated radiation therapy with concurrent cisplatin for stage Ib-Iva cervical cancer: an international multi-center phase II clinical trial (Intertecc-2). Int J Radiat Oncol Biol Phys. Forthcoming. DOI:10.1016/j.ijrobp.2016.11.027
   Web of Science ®Google Scholar